Company Overview of Emerillon Therapeutics Inc.
Emerillon Therapeutics, Inc., a biotechnology company, engages in the discovery and development of genomics-based drugs for infectious diseases. The company, through its recombinant congenic strains (RCS) mouse platform technology, discovers and develops drugs for human complex diseases. Its RCS mouse platform focuses on identifying drug targets in the fields of pain, atherosclerosis, osteoporosis, and epilepsy. Emerillon Therapeutics also offers contract services, such as mutation detection using dHPLC, mouse genotyping, and speed congenesis. The company was founded in 2003 and is based in Montréal, Canada.
416 de Maisonneuve West
Montréal, QC H3A 1L2
Founded in 2003
Key Executives for Emerillon Therapeutics Inc.
Similar Private Companies By Industry
|Dragon Pharmaceutical Inc.||Americas|
|ID Biomedical Corporation of Quebec||Americas|
|Kerr Investment Holding Corp.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
- Orlando, FL | Consult SoftPosted: May 22
Sponsored Financial Commentaries
To contact Emerillon Therapeutics Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.